Biologic response modifier agents for adults with rheumatoid arthritis

Canadian Agency for Drugs and Technologies in Health (CADTH)
Record ID 32012000842
English
Authors' objectives: Following failure of a disease-modifying antirheumatic drug (DMARD), the addition of a biologic is often considered the next step in therapy. Given the increasing use of biologic therapies to treat RA, health care providers, patients, and policymakers need evidence-based information to support optimal use of biologics and decision-making. The comparative effectiveness, harms, and costeffectiveness of the eight biologic therapies (including five TNF-alpha inhibitors) is unknown. Optimal treatment strategies in patients failing an initial TNF-alpha inhibitor are also unclear.
Authors' recommendations: The clinical and economic evaluations were used by the Therapeutic Review Panel to generate recommendations about the optimal use of biologic response modifier agents in the treatment of RA. Intervention tools to support the implementation of Therapeutic Review Panel recommendations and evidence-based optimal prescribing and use of biologics in the treatment of RA were developed.
Details
Project Status: Completed
Year Published: 2010
URL for published report: http://www.cadth.ca/en/products/therapeutic-reviews/about-therapeutic-reviews/pilot
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Antirheumatic Agents
  • Receptors, Tumor Necrosis Factor
  • Immunologic Factors
  • Immunoglobulin G
  • Biological Products
Contact
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name: requests@cadth.ca
Contact Email: requests@cadth.ca
Copyright: Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.